BioSpace News Archive

Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG) (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), today provided a business update and announced its operating and financial results for the third quarter of fiscal 2020 ended December 31, 2019

Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the appointment of Loretta Itri, M.D. as chief medical officer (CMO), effective today.

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has received special authorization from Health Canada to initiate a research program

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has received the Conformité Européene (CE) Mark approval for the Initial Serological Disease Screening (SDS) Microarray.

Noxopharm (ASX: NOX) is pleased to announce positive interim results from its LuPIN Phase 1/2 clinical trial. The data was presented during a poster presentation at the ASCO Genitourinary Cancers (GU) Symposium 2020 in San Francisco by St. Vincent’s Hospital Sydney.

AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth”), the third largest provider of home medical equipment (“HME”) in the United States, announced today that management is scheduled to present at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 27, 2020 at 9:30 am Eastern Time.

Today, IntraHealth International’s board of directors announced Polly Dunford will be IntraHealth’s next president and CEO

Premier orthopedic practice will add 27 new providers to Banner’s employed medical group

In the last quarter of 2019, we achieved a major milestone: the full recruitment of 200 patients for Part A of our pivotal Phase 3 study, NefIgArd.

Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today reported financial results for its fiscal third quarter ending December 31, 2019.